Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, only limited data exist for patients with cancer under systemic therapy. Based on this, our site has initiated a study evaluating safety and efficacy of SARS-CoV-2 vaccination in patients with solid and hematological malignancies under several systemic therapies. The initial results of the cohort of 59 patients receiving Immune Checkpoint Inhibitors are presented here. Despite no new safety issues have been noticed, the levels of SARS-CoV-2 neutralizing antibodies are significantly lower in comparison to matched healthy volunteers up to day 22 post the first dose. These results should be taken into consideration for the patients under treatment. Supplementary Information The online version contains supplementary material available at 10.1186/s13045-021-01099-x.
【저자키워드】 SARS-CoV-2, vaccination, Cancer, BNT162b2, AZD1222, Immune checkpoint inhibitors, 【초록키워드】 Treatment, Efficacy, therapy, Neutralizing antibodies, Hematological malignancy, Hematological malignancies, Infection, Cohort, Patient, General population, systemic therapy, SARS-CoV-2 neutralizing antibodies, Therapies, SARS-CoV-2 vaccination, SARS-CoV-2 neutralizing antibody, Immune checkpoint inhibitors, Patients with cancer, supplementary material, first dose, significantly lower, initial, the patient, receiving, provide, initiated, healthy volunteer, 【제목키워드】 inhibitor, SARS-CoV-2 neutralizing antibody, dose, cancer patient, first vaccination, receiving,